Review





Similar Products

anti-rbpms antibody  (Antibodies Inc)
96
Antibodies Inc anti-rbpms antibody
Anti Rbpms Antibody, supplied by Antibodies Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-rbpms antibody/product/Antibodies Inc
Average 96 stars, based on 1 article reviews
anti-rbpms antibody - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
splicing rbpms antibody  (Proteintech)
95
Proteintech splicing rbpms antibody
Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of <t>RBPMS</t> staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; <t>RBPMS:</t> <t>RNA</t> binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.
Splicing Rbpms Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/splicing rbpms antibody/product/Proteintech
Average 95 stars, based on 1 article reviews
splicing rbpms antibody - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
rabbit anti rbpms  (Proteintech)
95
Proteintech rabbit anti rbpms
Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of <t>RBPMS</t> staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; <t>RBPMS:</t> <t>RNA</t> binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.
Rabbit Anti Rbpms, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti rbpms/product/Proteintech
Average 95 stars, based on 1 article reviews
rabbit anti rbpms - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
15187 1 ap  (Proteintech)
95
Proteintech 15187 1 ap
Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of <t>RBPMS</t> staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; <t>RBPMS:</t> <t>RNA</t> binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.
15187 1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/15187 1 ap/product/Proteintech
Average 95 stars, based on 1 article reviews
15187 1 ap - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
anti rbpms  (Proteintech)
95
Proteintech anti rbpms
Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of <t>RBPMS</t> staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; <t>RBPMS:</t> <t>RNA</t> binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.
Anti Rbpms, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti rbpms/product/Proteintech
Average 95 stars, based on 1 article reviews
anti rbpms - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
mrna processing factor rbpms  (Proteintech)
95
Proteintech mrna processing factor rbpms
Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of <t>RBPMS</t> staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; <t>RBPMS:</t> <t>RNA</t> binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.
Mrna Processing Factor Rbpms, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mrna processing factor rbpms/product/Proteintech
Average 95 stars, based on 1 article reviews
mrna processing factor rbpms - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

Image Search Results


Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of RBPMS staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; RBPMS: RNA binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.

Journal: Neural Regeneration Research

Article Title: Synapses and dendritic spines are eliminated in the primary visual cortex of mice subjected to chronic intraocular pressure elevation

doi: 10.4103/NRR.NRR-D-24-00394

Figure Lengend Snippet: Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of RBPMS staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; RBPMS: RNA binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.

Article Snippet: The retinas were permeabilized using 2% Triton X-100, followed by a 2-hour blocking step with 5% goat serum (Boster, Wuhan, China), and subsequently incubated overnight at 4°C with an anti-RNA binding protein with multiple splicing (RBPMS) antibody (rabbit, 1:100, ProteinTech, Rosemont, IL, USA, Cat# 15187-1-AP, RRID: AB_2238431).

Techniques: Injection, Control, Staining, RNA Binding Assay